These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3817604)

  • 41. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
    Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
    Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence of venous thromboembolism in users of combined oral contraceptives. Risk is particularly high with first use of oral contraceptives.
    Vandenbrouke JP; Bloemenkamp KW; Rosendaal FR; Helmerhorst FM
    BMJ; 2000 Jan; 320(7226):57-8. PubMed ID: 10671043
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of some drugs on thromboplastin (factor III) activity of human monocytes in vitro.
    Prydz H; Lyberg T
    Biochem Pharmacol; 1980 Jan; 29(1):9-14. PubMed ID: 6244830
    [No Abstract]   [Full Text] [Related]  

  • 44. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitory effect of 3-deazaadenosine on the thromboplastin response of stimulated human monocytes.
    Hetland O; Brovold AB; Prydz H
    Thromb Res; 1985 Jan; 37(1):135-43. PubMed ID: 3983895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thromboembolism and the combined oral contraceptive.
    Girard M
    Lancet; 1995 Jul; 346(8970):317. PubMed ID: 7677919
    [No Abstract]   [Full Text] [Related]  

  • 48. Oral contraceptive 'potencies' and deep venous thromboembolism.
    Edgren RA
    Int J Epidemiol; 1992 Apr; 21(2):420-1. PubMed ID: 1428500
    [No Abstract]   [Full Text] [Related]  

  • 49. The development of monospecific antibodies against human thromboplastin apoprotein (apoprotein III) and their application in the immunocytochemical detection of the antigen in blood cells.
    Bjørklid E; Holm T; Osterud B
    Thromb Res; 1987 Mar; 45(5):609-24. PubMed ID: 2438802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thromboplastin (tissue factor) in plasma membranes of human monocytes.
    Hetland O; Brovold AB; Holme R; Gaudernack G; Prydz H
    Biochem J; 1985 Jun; 228(3):735-43. PubMed ID: 4026807
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of immune complex-containing sera from patients with rheumatic diseases on thromboplastin activity of monocytes.
    Lyberg T; Prydz H; Baklien K; Høyeraal HM
    Thromb Res; 1982 Feb; 25(3):193-202. PubMed ID: 6977888
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thromboembolism and the combined oral contraceptive pill.
    Pasi KJ; Perry DJ; Lee CA
    Lancet; 1995 Jun; 345(8962):1437. PubMed ID: 7677845
    [No Abstract]   [Full Text] [Related]  

  • 53. In vitro stimulation of tissue thromboplastin (factor III) activity in human monocytes by immune complexes and lectins.
    Prydz H; Lyberg T; Deteix P; Allison AC
    Thromb Res; 1979; 15(3-4):465-74. PubMed ID: 494155
    [No Abstract]   [Full Text] [Related]  

  • 54. Combined oral contraceptives and thromboembolism.
    Rawlins M
    BMJ; 1995 Nov; 311(7014):1232. PubMed ID: 7488933
    [No Abstract]   [Full Text] [Related]  

  • 55. Cardiovascular disease and oral contraceptive use.
    Bromham DR; Skouby SO
    Eur J Contracept Reprod Health Care; 1996; 1(1):1-2. PubMed ID: 9678131
    [No Abstract]   [Full Text] [Related]  

  • 56. [Influence of endotoxin-stimulated monocytes on the exogenous coagulation system].
    Hiller E; Saal JG; Griffiths GW
    Blut; 1977 May; 34(5):409-12. PubMed ID: 871538
    [No Abstract]   [Full Text] [Related]  

  • 57. Thromboplastin as a marker for monocyte differentiation.
    Lyberg T; Ivhed I; Prydz H; Nilsson K
    Br J Haematol; 1983 Feb; 53(2):327-35. PubMed ID: 6821657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monocyte tissue factor activity in anticoagulant-treated patients.
    Zacharski LR; Beck JR
    Thromb Res; 1983 Jan; 29(2):207-13. PubMed ID: 6845276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trans mono-unsaturated fatty acids and tissue factor activity in a monocytic cell line.
    Bunce T; Jacobs M; Bruckdorfer KR
    Biochem Soc Trans; 1998 May; 26(2):S157. PubMed ID: 9649832
    [No Abstract]   [Full Text] [Related]  

  • 60. Inflammatory particles stimulate thromboplastin production by human monocytes.
    Dean RT; Prydz H
    Thromb Res; 1983 May; 30(4):357-67. PubMed ID: 6193600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.